Kepler Cheuvreux upgraded Bayer (BAYRY) to Buy from Hold with an unchanged price target of EUR 33. All of Bayer’s operational problems and a “good chunk of the worst-case scenario” on the litigation front are priced into shares, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BAYRY:
- Bayer upgraded to Buy from Neutral at Goldman Sachs
- Bayer price target raised to EUR 28 from EUR 26 at Morgan Stanley
- Bayer says FDA accepts NDA under priority review for sevabertinib
- Bayer price target raised to EUR 25 from EUR 22 at Barclays
- Trump Trade: Trump considers 50% tariff on EU, 25% on iPhones